Factors related to compliance with adjuvant chemotherapy in patients with gastric cancer: A retrospective single-center study

Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative sur...

Full description

Saved in:
Bibliographic Details
Published inKorean journal of clinical oncology Vol. 17; no. 1; pp. 31 - 36
Main Authors Jin, Geon Yi, Park, Ki Bum, Song, Kyo Young
Format Journal Article
LanguageEnglish
Published Korea (South) 대한종양외과학회 01.06.2021
Korean Society of Surgical Oncology
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
AbstractList Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.PurposeAdjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC.The data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).MethodsThe data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX).The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).ResultsThe study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively).Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.ConclusionOld age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. Methods: The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). Results: The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Conclusion: Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen. KCI Citation Count: 0
Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. The data of patients who underwent curative gastrectomy for pathologic stage II-III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
Purpose Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not receive or complete chemotherapy. This study aimed to identify factors related to patient compliance with chemotherapy after curative surgery for advanced GC. Methods The data of patients who underwent curative gastrectomy for pathologic stage II–III GC between 2012 and 2016 were reviewed. Patients were divided into an AC completion group (group C), AC incompletion group (group I), and surgery-only group (group S). The AC regimen was either tegafur/gimeracil/oteracil (S-1) or capecitabine plus oxaliplatin (XELOX). Results The study enrolled 417 patients; group C had 222 patients, group I had 110, and group S had 85. The most common reason for not initiating AC was poor general condition (36.5%), while chemotherapy-related complications was the common reason for AC incompletion (43.6%). In multivariate analysis, age over 65 years, Eastern Cooperative Oncology Group performance status ≥1, Charlson comorbidity index ≥1, and the presence of postoperative complications were independent risk factors for not initiating AC (odds ratio: 4.32, 2.62, 1.84, and 2.17, respectively). Age over 65 years, longer postoperative stay, and XELOX regimen were significant risk factors for incompletion of AC (odds ratio: 2.68, 1.72, and 2.23, respectively). Conclusion Old age, poor performance status, comorbidities, and postoperative complications, longer postoperative hospital stay, and XELOX regimen were associated with poor compliance with AC in GC patients. Clinicians can improve compliance with AC by managing postoperative complications and selecting the most appropriate treatment regimen.
Author Geon Yi Jin
Kyo Young Song
Ki Bum Park
AuthorAffiliation 1 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2 Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
AuthorAffiliation_xml – name: 1 Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
– name: 2 Department of Surgery, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Author_xml – sequence: 1
  givenname: Geon Yi
  orcidid: 0000-0002-1705-5513
  surname: Jin
  fullname: Jin, Geon Yi
– sequence: 2
  givenname: Ki Bum
  orcidid: 0000-0001-6035-6584
  surname: Park
  fullname: Park, Ki Bum
– sequence: 3
  givenname: Kyo Young
  orcidid: 0000-0002-5840-1638
  surname: Song
  fullname: Song, Kyo Young
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36945212$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738181$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNpVkktvEzEQgFeoiJbSE3e0FyQQ2mJ7_eSAFJUWIlVUQuVsOfZs4mSzXmxvUA78dzYPInoayf7mG49nXhZnXeigKF5jdI0pwfzjamnDNcEIsWfFBSFSVhRJelZcYFHLSiJJzourlJYIIaJIjWv-ojivuaKMYHJR_LkzNoeYygityeDKHEob1n3rTWeh_O3zojRuOWxMl0u7gHXIC4im35a-K3uTPXQ5HbC5STl6W9pdZvxUTkZnjiH1YLPfQJl8N2-hsmMGxDLlwW1fFc8b0ya4OsbL4ufd7ePNt-r-4ev0ZnJf2RpTVnGMG-OcVUwQ4kBZQVltmhlhuGmEAIG4JKJR0DhGhawtV5YZZ7lwjjE1qy-L9wdvFxu9sl4H4_dxHvQq6smPx6lWklJE2MhOD6wLZqn76NcmbvcJ-4MQ59rE7G0LWjbARc2klaCoqbHktbKI1A0HYAKa0fX54OqH2RrcrvVo2ifSpzedX4xv2milKBGUj4J3R0EMvwZIWa99stC2poMwJE2EVAIjytGIvvm_1qnIv1mPwIcDYMehpAjNCcFI75dJ75ZJ75dppN8ev2wYKXDenPDvD19uMWKS87Hhv9v1yxU
Cites_doi 10.1371/journal.pone.0186362
10.1007/s10120-012-0158-1
10.1056/nejmoa072252
10.1245/s10434-018-7063-8
10.1245/s10434-018-6375-z
10.1016/s0140-6736(11)61873-4
10.1016/j.jclinepi.2004.03.012
10.1245/s10434-014-4296-z
10.5230/jgc.2020.20.e13
10.3892/ol.2020.11893
10.1007/s10120-018-0869-z
10.1245/s10434-017-5923-2
10.1016/j.ejso.2017.01.239
10.4174/astr.2019.96.4.185
10.7150/jca.27753
10.5230/jgc.2012.12.2.55
10.5230/jgc.2018.18.e4
ContentType Journal Article
Copyright Copyright © 2021 Korean Society of Surgical Oncology.
Copyright © 2021 Korean Society of Surgical Oncology 2021
Copyright_xml – notice: Copyright © 2021 Korean Society of Surgical Oncology.
– notice: Copyright © 2021 Korean Society of Surgical Oncology 2021
DBID DBRKI
TDB
AAYXX
CITATION
NPM
7X8
5PM
DOA
ACYCR
DOI 10.14216/kjco.21005
DatabaseName DBPIA - 디비피아
Nurimedia DBPIA Journals
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 2288-4084
EndPage 36
ExternalDocumentID oai_kci_go_kr_ARTI_9844025
oai_doaj_org_article_8fe67358c8e94a318639c023f6ee57ef
PMC9942746
36945212
10_14216_kjco_21005
NODE10586686
Genre Journal Article
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
DBRKI
GROUPED_DOAJ
GW5
PGMZT
RPM
TDB
AAYXX
CITATION
NPM
7X8
5PM
ACYCR
ID FETCH-LOGICAL-c3145-611faddc95722de9c7453afb251ff77e706827f9efd54783c69c5adc67dd559b3
IEDL.DBID DOA
ISSN 1738-8082
2288-4084
IngestDate Thu Dec 19 03:18:36 EST 2024
Wed Aug 27 01:29:29 EDT 2025
Thu Aug 21 18:37:29 EDT 2025
Fri Jul 11 02:49:01 EDT 2025
Thu Jan 02 22:53:06 EST 2025
Tue Jul 01 02:40:47 EDT 2025
Thu Feb 06 13:21:34 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Adjuvant chemotherapy
Gastrectomy
Gastric cancer
Patient compliance
Language English
License Copyright © 2021 Korean Society of Surgical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3145-611faddc95722de9c7453afb251ff77e706827f9efd54783c69c5adc67dd559b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
https://doi.org/10.14216/kjco.21005
ORCID 0000-0002-1705-5513
0000-0001-6035-6584
0000-0002-5840-1638
OpenAccessLink https://doaj.org/article/8fe67358c8e94a318639c023f6ee57ef
PMID 36945212
PQID 2789710460
PQPubID 23479
PageCount 6
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9844025
doaj_primary_oai_doaj_org_article_8fe67358c8e94a318639c023f6ee57ef
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9942746
proquest_miscellaneous_2789710460
pubmed_primary_36945212
crossref_primary_10_14216_kjco_21005
nurimedia_primary_NODE10586686
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20210601
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 6
  year: 2021
  text: 20210601
  day: 1
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Korean journal of clinical oncology
PublicationTitleAlternate Korean J Clin Oncol
PublicationYear 2021
Publisher 대한종양외과학회
Korean Society of Surgical Oncology
Publisher_xml – name: 대한종양외과학회
– name: Korean Society of Surgical Oncology
References ref13
ref12
ref15
ref14
ref20
ref11
ref21
(ref1) 2019
ref17
ref16
ref19
ref8
ref7
(ref2) 2017
ref9
ref4
ref3
Eek (ref18) 2016
ref6
ref5
Clavien (ref10) 2009
References_xml – ident: ref17
  doi: 10.1371/journal.pone.0186362
– ident: ref19
  doi: 10.1007/s10120-012-0158-1
– ident: ref3
  doi: 10.1056/nejmoa072252
– ident: ref16
  doi: 10.1245/s10434-018-7063-8
– start-page: 1
  volume-title: Korean practice guideline for gastric cancer 2018: an evidence-based, multi-disciplinary approach
  year: 2019
  ident: ref1
– ident: ref7
  doi: 10.1245/s10434-018-6375-z
– ident: ref4
  doi: 10.1016/s0140-6736(11)61873-4
– ident: ref9
  doi: 10.1016/j.jclinepi.2004.03.012
– start-page: 187
  volume-title: The Clavien-Dindo classification of surgical complications: five-year experience
  year: 2009
  ident: ref10
– ident: ref12
  doi: 10.1245/s10434-014-4296-z
– ident: ref8
  doi: 10.5230/jgc.2020.20.e13
– ident: ref5
  doi: 10.3892/ol.2020.11893
– ident: ref21
  doi: 10.1007/s10120-018-0869-z
– start-page: 1609
  volume-title: Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature
  year: 2016
  ident: ref18
– start-page: 1
  volume-title: Japanese gastric cancer treatment guidelines 2014 (ver. 4)
  year: 2017
  ident: ref2
– ident: ref15
  doi: 10.1245/s10434-017-5923-2
– ident: ref11
  doi: 10.1016/j.ejso.2017.01.239
– ident: ref13
  doi: 10.4174/astr.2019.96.4.185
– ident: ref6
  doi: 10.7150/jca.27753
– ident: ref20
  doi: 10.5230/jgc.2012.12.2.55
– ident: ref14
  doi: 10.5230/jgc.2018.18.e4
SSID ssj0002923136
ssib059951131
Score 2.1468742
Snippet Purpose: Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do...
Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do not...
Purpose Adjuvant chemotherapy (AC) improves survival outcomes in patients with advanced gastric cancer (GC) after curative surgery; however, some patients do...
SourceID nrf
doaj
pubmedcentral
proquest
pubmed
crossref
nurimedia
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 31
SubjectTerms adjuvant chemotherapy
gastrectomy
gastric cancer
Original
patient compliance
일반외과학
Title Factors related to compliance with adjuvant chemotherapy in patients with gastric cancer: A retrospective single-center study
URI https://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE10586686
https://www.ncbi.nlm.nih.gov/pubmed/36945212
https://www.proquest.com/docview/2789710460
https://pubmed.ncbi.nlm.nih.gov/PMC9942746
https://doaj.org/article/8fe67358c8e94a318639c023f6ee57ef
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002738181
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX 대한종양외과학회지, 2021, 17(1), , pp.31-36
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQL-WCqMojPFYG9Rq6iR0_uLWwq4JEuVCpNyuZ2GW7JUFp9tAD_PbOONnVLkLiwmVXm02cxN_YM2PPfMPYEQ4fAzmYVIGGVAot00rmkNahFChQUIkhQPZcnV3Iz5fF5VapL4oJG-iBh447NsErLQoDxltZogSiSgVUNEF5X2gfaPZFnbflTKEkEYtWlo37WzQn52THxHqBmcYRblDxjcl6Ms_U8fIa2nfo_FARuy31FFn8Uek0Hf7Yb1ZEuI-o_c0Y_TOmcktJzR-zR6N1yU-GtzpgD3xzyH7Nh5o6POat-Jr3LR8iyQlxTiuxvKyvV2hT9xwx_DEmZd3xRcNH3tXb4bSrksp8AAe6snvPT7DNvmvX6ZqcFh5ufEpP5zseqWufsIv57NuHs3SsupCCyGSBvmQWcNIDW-g8r70FLQtRhgoNoRC09nqqTK6D9aEmLjABykJR1qB0XaN7UomnbK9pG_-ccV8FqApdE-eLVCArA9NpsJkAi1aErRJ2tO5s93Mg13DklBAmjjBxEZOEnRIQm1OIETseQDlxo5y4f8lJwt4ijG4Ji3g9fV-1btk59Bs-OWskOtJ4p8kG5c3tzr9-nKEVapQyKmFv1tA7HIe0uVI2vl3dOsoo1rRhPk3Ys0EUNi0IZSXlSCdM7wjJzhvt_tMsvkeub2tlrqV68T-64CV7mFNETlxDesX2-m7lX6NJ1VeTOHrw88vv2SSueN0DTB8gtg
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factors+related+to+compliance+with+adjuvant+chemotherapy+in+patients+with+gastric+cancer%3A+A+retrospective+single-center+study&rft.jtitle=Korean+journal+of+clinical+oncology&rft.au=Geon+Yi+Jin&rft.au=Ki+Bum+Park&rft.au=%EC%86%A1%EA%B5%90%EC%98%81&rft.date=2021-06-01&rft.pub=%EB%8C%80%ED%95%9C%EC%A2%85%EC%96%91%EC%99%B8%EA%B3%BC%ED%95%99%ED%9A%8C&rft.issn=1738-8082&rft.eissn=2288-4084&rft.spage=31&rft.epage=36&rft_id=info:doi/10.14216%2Fkjco.21005&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_9844025
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1738-8082&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1738-8082&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1738-8082&client=summon